Y Kör1, M Keskin2. 1. Adana Numune Training and Research Hospital, Pediatrics Clinic, Pediatric Endocrinology Division, Adana, Turkey. 2. Gaziantep University Faculty of Medicine, Dept. of Pediatric Endocrinology, Gaziantep, Turkey.
Abstract
BACKGROUND/AIMS: Growth hormone (GH) treatment has severe cost burden on patients, their families, and healthcare systems. Therefore, accuracy of diagnosis should be confirmed; factors affecting the response to treatment should be defined. The present study is performed to evaluate auxiliary diagnostic parameters and factors affecting treatment in growth hormone deficiency (GHD). METHODS: In this study, 142 patients under the age of 16, with at least one year of treatment, were included. Treatment dose of somatropin was 0.2 mg/kg/week in all cases. Response to treatment was evaluated by measuring annual height and height standard deviation score (SDS) gains every 3 months. RESULTS: Male to female ratio was 79 to 63, and follow-up duration before the treatment was 0.89±0.38 years. Annual growth rate before the treatment was 2.92±1.02 cm, and age at the treatment initiation was 9.97±3.22 years. Height gain SDS at the end of the first year was significantly higher in cases which were at the prepuberty, had severe short stature, low height SDS-mid parental height SDS (HSDS-MPHSDS), and initiated treatment at earlier ages. Correlations in height gain and height SDS gain at the end of the first year were significant between bone age at treatment baseline, delta SDS factors, L-dopa and clonidine stimulation results (both are p<0.01). CONCLUSION: Height gain was positively related to body mass index, whereas negatively to bone age at treatment baseline, responses obtained from stimulation tests, and delta SDS values. In the treatment evaluation, the parameters which can affect according to model chosen by the investigator, may differ.
BACKGROUND/AIMS: Growth hormone (GH) treatment has severe cost burden on patients, their families, and healthcare systems. Therefore, accuracy of diagnosis should be confirmed; factors affecting the response to treatment should be defined. The present study is performed to evaluate auxiliary diagnostic parameters and factors affecting treatment in growth hormone deficiency (GHD). METHODS: In this study, 142 patients under the age of 16, with at least one year of treatment, were included. Treatment dose of somatropin was 0.2 mg/kg/week in all cases. Response to treatment was evaluated by measuring annual height and height standard deviation score (SDS) gains every 3 months. RESULTS: Male to female ratio was 79 to 63, and follow-up duration before the treatment was 0.89±0.38 years. Annual growth rate before the treatment was 2.92±1.02 cm, and age at the treatment initiation was 9.97±3.22 years. Height gain SDS at the end of the first year was significantly higher in cases which were at the prepuberty, had severe short stature, low height SDS-mid parental height SDS (HSDS-MPHSDS), and initiated treatment at earlier ages. Correlations in height gain and height SDS gain at the end of the first year were significant between bone age at treatment baseline, delta SDS factors, L-dopa and clonidine stimulation results (both are p<0.01). CONCLUSION: Height gain was positively related to body mass index, whereas negatively to bone age at treatment baseline, responses obtained from stimulation tests, and delta SDS values. In the treatment evaluation, the parameters which can affect according to model chosen by the investigator, may differ.
Entities:
Keywords:
body height; body mass index; child; growth disorders; human growth hormone
Authors: Thomas A Wilson; Susan R Rose; Pinchas Cohen; Alan D Rogol; Philippe Backeljauw; Rosalind Brown; Dana S Hardin; Stephen F Kemp; Margaret Lawson; Sally Radovick; Stephen M Rosenthal; Lawrence Silverman; Phyllis Speiser Journal: J Pediatr Date: 2003-10 Impact factor: 4.406
Authors: Stephen F Kemp; Joyce Kuntze; Kenneth M Attie; Thomas Maneatis; S Butler; James Frane; Barbara Lippe Journal: J Clin Endocrinol Metab Date: 2005-07-05 Impact factor: 5.958
Authors: Pinchas Cohen; George M Bright; Alan D Rogol; Anne-Marie Kappelgaard; Ron G Rosenfeld Journal: J Clin Endocrinol Metab Date: 2002-01 Impact factor: 5.958
Authors: E Schönau; F Westermann; F Rauch; A Stabrey; G Wassmer; E Keller; J Brämswig; W F Blum Journal: Eur J Endocrinol Date: 2001-01 Impact factor: 6.664
Authors: Werner F Blum; Kalotina Machinis; Elena P Shavrikova; Alexandra Keller; Heike Stobbe; Roland W Pfaeffle; Serge Amselem Journal: J Clin Endocrinol Metab Date: 2006-07-25 Impact factor: 5.958
Authors: Edward O Reiter; David A Price; Patrick Wilton; Kerstin Albertsson-Wikland; Michael B Ranke Journal: J Clin Endocrinol Metab Date: 2006-03-14 Impact factor: 5.958